Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.65 |
| ▸ | AXL | P30530 | 10/20 | 0.60 |
| ▸ | MET | P08581 | 4/20 | 0.60 |
| ▸ | EGFR | P00533 | 3/20 | 0.60 |
| ▸ | SRC | P12931 | 3/20 | 0.60 |
| ▸ | RET | P07949 | 2/20 | 0.60 |
| ▸ | PLK4 | O00444 | 2/20 | 0.60 |
| ▸ | GAK | O14976 | 2/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.60 |
| ▸ | ERN1 | O75460 | 2/20 | 0.60 |
| ▸ | STK10 | O94804 | 2/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.60 |
| ▸ | FYN | P06241 | 2/20 | 0.60 |
| ▸ | YES1 | P07947 | 2/20 | 0.60 |
| ▸ | LYN | P07948 | 2/20 | 0.60 |
| ▸ | FER | P16591 | 2/20 | 0.60 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.60 |
| ▸ | ABL2 | P42684 | 2/20 | 0.60 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240816 | 0.96 | KDR (0.66) | KDRPDGFRBAXLMETEGFR | |
| SCHEMBL242803 | 0.93 | KDR (0.63) | KDRPDGFRBAXLMETEGFR | |
| SCHEMBL245590 | 0.89 | KDR (0.64) | KDRPDGFRBAXLMETEGFR | |
| SCHEMBL15966415 | 0.86 | KDR (0.69) | KDRPDGFRBAXLMETEGFR | |
| SCHEMBL15966463 | 0.85 | KDR (0.74) | KDRPDGFRBAXLMETEGFR | |
| SCHEMBL242187 | 0.85 | KDR (0.63) | KDRPDGFRBAXLMETEGFR | |
| SCHEMBL15966461 | 0.85 | KDR (0.81) | KDRPDGFRBAXLMETEGFR | |
| SCHEMBL242042 | 0.84 | KDR (0.62) | KDRPDGFRBAXLMETEGFR | |
| SCHEMBL19668836 | 0.84 | MET (0.68) | KDRPDGFRBAXLMETEGFR | |
| SCHEMBL10296354 | 0.84 | KDR (0.61) | KDRPDGFRBAXLMETEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2312950-B1 | COMPOUNDS AS KINASE INHIBITORS | ADVENCHEN LAB LLC (US) | 2016-11-30 | — | — | EP | claimed |
| US-8211911-B2 | Compounds as kinase inhibitors | CHEN GUOQING PAUL (US) | 2012-07-03 | — | — | US | claimed |
| JP-2012500269-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-2312950-A1 | COMPOUNDS AS KINASE INHIBITORS | Advenchen Laboratories, LLC (US) | 2011-04-27 | — | — | EP | claimed |
| US-20100048599-A1 | Compounds As Kinase Inhibitors | CHEN GUOQING PAUL | 2010-02-25 | — | — | US | claimed |
| WO-2010021918-A1 | COMPOUNDS AS KINASE INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2010-02-25 | — | — | WO | claimed |
| EP-2312950-B1 | COMPOUNDS AS KINASE INHIBITORS | ADVENCHEN LAB LLC (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2312950-B1 | COMPOUNDS AS KINASE INHIBITORS | ADVENCHEN LAB LLC (US) | 2016-11-30 | — | — | EP | disclosed |
| US-8211911-B2 | Compounds as kinase inhibitors | CHEN GUOQING PAUL (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211911-B2 | Compounds as kinase inhibitors | CHEN GUOQING PAUL (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211911-B2 | Compounds as kinase inhibitors | CHEN GUOQING PAUL (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2312950-A1 | COMPOUNDS AS KINASE INHIBITORS | Advenchen Laboratories, LLC (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20100048599-A1 | Compounds As Kinase Inhibitors | CHEN GUOQING PAUL | 2010-02-25 | — | — | US | disclosed |
| US-20100048599-A1 | Compounds As Kinase Inhibitors | CHEN GUOQING PAUL | 2010-02-25 | — | — | US | disclosed |
| US-20100048599-A1 | Compounds As Kinase Inhibitors | CHEN GUOQING PAUL | 2010-02-25 | — | — | US | disclosed |
| WO-2010021918-A1 | COMPOUNDS AS KINASE INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010021918-A1 | COMPOUNDS AS KINASE INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048599-A1 | Compounds As Kinase Inhibitors | MAP3K1, MAP3K5, MAP3K6 | KDR 44/4885PDGFRB 148/4885AXL 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.